The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma.

Sylvester researchers have become the first to look at trends in alcohol-linked cancer mortality across the U.S. Their findings, presented last month ...

Scottish swimmer Archie Goodburn was diagnosed with oligodendrogliomas at just 23 Here’s all you need to know about the rare ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

While surgery using 5-aminolevulinic acid improves total resection rates in high-grade glioma, the best outcomes are seen ...

Our strategic approach is about advancing science to benefit patients most in need of new therapies. As a private company led ...

With the intent of dissecting the molecular complexity of Philadelphia-negative myeloproliferative neoplasms (MPN), we designed a target enrichment panel to explore, using next-generation ...

Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial ...

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.

Servier India, a subsidiary of the leading French pharmaceutical Servier Group, recently announced the launch of Ivosidenib (Tibsovo), an oral targeted therapy approved in the management of cancer ...

Gliomas are among the most aggressive brain tumors, with glioblastoma offering a median survival of 12 to 15 months. Despite advances in surgical, ...

Background: CCA is a rare cancer for which there are limited effective therapies. IDH1 mutations occur in ̃20% of intrahepatic CCAs, resulting in production of the oncometabolite D-2-hydroxyglutarate, ...